Dennis A. Priebat

7.9k total citations · 2 hit papers
37 papers, 5.2k citations indexed

About

Dennis A. Priebat is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Dennis A. Priebat has authored 37 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 11 papers in Gastroenterology. Recurrent topics in Dennis A. Priebat's work include Sarcoma Diagnosis and Treatment (23 papers), Gastrointestinal Tumor Research and Treatment (11 papers) and Soft tissue tumor case studies (5 papers). Dennis A. Priebat is often cited by papers focused on Sarcoma Diagnosis and Treatment (23 papers), Gastrointestinal Tumor Research and Treatment (11 papers) and Soft tissue tumor case studies (5 papers). Dennis A. Priebat collaborates with scholars based in United States, Canada and Ukraine. Dennis A. Priebat's co-authors include Gerald Rothstein, Robert D. Christensen, Laurence H. Baker, Robert G. Maki, J. Kyle Wathen, Shreyaskumar Patel, Brian L. Samuels, Robert S. Benjamin, Denise K. Reinke and Scott M. Schuetze and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Dennis A. Priebat

36 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker

1982 3.2k citations Dennis A. Priebat et al. profile →
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

2007 531 citations Robert G. Maki, J. Kyle Wathen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dennis A. Priebat United States	20	1.6k	1.0k	998	820	809	37	5.2k
Shri N. Giri United States	41	2.6k 1.7×	504 0.5×	1.3k 1.3×	430 0.5×	501 0.6×	198	5.7k
Jinhua Li China	38	626 0.4×	456 0.4×	2.8k 2.8×	579 0.7×	757 0.9×	148	6.3k
Fumitaka Ohsuzu Japan	42	780 0.5×	328 0.3×	975 1.0×	854 1.0×	1.0k 1.2×	204	5.0k
Antonio Domenico Procopio Italy	52	1.3k 0.8×	1.3k 1.3×	3.5k 3.5×	1.5k 1.8×	455 0.6×	181	8.1k
Vincent Lagente France	44	2.3k 1.4×	557 0.5×	2.3k 2.3×	1.5k 1.8×	543 0.7×	187	7.1k
Jerzy Stachura Poland	40	1.0k 0.6×	835 0.8×	1.3k 1.3×	435 0.5×	2.8k 3.4×	290	6.0k
Sabina Janciauskiene Sweden	47	1.0k 0.6×	1.1k 1.1×	2.1k 2.1×	1.1k 1.3×	695 0.9×	176	6.5k
Jannis Kountouras Greece	47	1.4k 0.9×	930 0.9×	1.1k 1.1×	714 0.9×	3.2k 4.0×	223	6.8k
Choitsu Sakamoto Japan	42	948 0.6×	702 0.7×	1.4k 1.4×	453 0.6×	3.2k 4.0×	260	6.4k
Zhiwei Wang China	30	754 0.5×	592 0.6×	1.3k 1.3×	463 0.6×	445 0.6×	210	4.1k

Countries citing papers authored by Dennis A. Priebat

Since Specialization

Citations

This map shows the geographic impact of Dennis A. Priebat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis A. Priebat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis A. Priebat more than expected).

Fields of papers citing papers by Dennis A. Priebat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis A. Priebat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis A. Priebat. The network helps show where Dennis A. Priebat may publish in the future.

Co-authorship network of co-authors of Dennis A. Priebat

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis A. Priebat. A scholar is included among the top collaborators of Dennis A. Priebat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis A. Priebat. Dennis A. Priebat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burgess, Melissa, Vanessa Bolejack, Scott M. Schuetze, et al.. (2019). Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.. Journal of Clinical Oncology. 37(15_suppl). 11015–11015. 82 indexed citations

Burgess, Melissa, Vanessa Bolejack, Brian Andrew Van Tine, et al.. (2017). Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. Journal of Clinical Oncology. 35(15_suppl). 11008–11008. 31 indexed citations

Burgess, Melissa, Jason Roszik, Brian Andrew Van Tine, et al.. (2017). Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. Journal of Clinical Oncology. 35(7_suppl). 60–60. 3 indexed citations

Heinrich, Michael C., Cathryn Rankin, Charles D. Blanke, et al.. (2017). Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. JAMA Oncology. 3(7). 944–944. 69 indexed citations

Hensley, Martee L., J. Kyle Wathen, Robert G. Maki, et al.. (2013). Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma. Cancer. 119(8). 1555–1561. 116 indexed citations

Jelinek, James S., Dennis A. Priebat, & Francesca D. Beaman. (2013). Current Imaging and Therapy of Malignant Soft Tissue Tumors and Tumor-like Lesions. Seminars in Musculoskeletal Radiology. 17(2). 168–176. 16 indexed citations

Chugh, Rashmi, J. Kyle Wathen, Shreyaskumar Patel, et al.. (2010). Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. Clinical Cancer Research. 16(19). 4884–4891. 166 indexed citations

Amiri‐Kordestani, Laleh, Dennis A. Priebat, & Stanley H. Chia. (2010). Follicular Dendritic Cell Sarcoma of the Neck: Case Report and Review of Current Diagnostic and Management Strategies. Ear Nose & Throat Journal. 89(7). E14–E17. 9 indexed citations

Garcia, Carlos Alexandre Borges, et al.. (2009). Doxorubicin-Induced Cardiac Toxicity and Cardiac Rest Gated Blood Pool Imaging. Clinical Nuclear Medicine. 34(11). 762–767. 26 indexed citations

10.

Lakhani, Sunil R., et al.. (2008). Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatology International. 2(4). 498–499. 32 indexed citations

11.

Maki, Robert G., J. Kyle Wathen, Shreyaskumar Patel, et al.. (2007). Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. Journal of Clinical Oncology. 25(19). 2755–2763. 531 indexed citations breakdown →

12.

Maki, Robert G., Martee L. Hensley, J. Kyle Wathen, et al.. (2006). A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). Journal of Clinical Oncology. 24(18_suppl). 9514–9514. 10 indexed citations

13.

Chugh, Rashmi, Robert G. Maki, Denise K. Reinke, et al.. (2006). A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Journal of Clinical Oncology. 24(18_suppl). 9515–9515. 15 indexed citations

14.

Baker, Laurence H., Rashmi Chugh, Dominic Thomas, et al.. (2004). Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. Journal of Clinical Oncology. 22(14_suppl). 9013–9013. 4 indexed citations

15.

Chugh, Rashmi, Dafydd G. Thomas, Peter F. Thall, et al.. (2004). Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. Journal of Clinical Oncology. 22(14_suppl). 9001–9001. 12 indexed citations

16.

Okuno, Scott H., Louise Ryan, John H. Edmonson, Dennis A. Priebat, & Ronald H. Blum. (2003). Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). Cancer. 97(8). 1969–1973. 57 indexed citations

17.

Allweis, Tanir M., et al.. (2002). Immediate reconstruction after mastectomy for breast cancer does not prolong the time to starting adjuvant chemotherapy. The American Journal of Surgery. 183(3). 218–221. 77 indexed citations

18.

Ringel, Matthew D., Max Greenberg, Koichi Suzuki, et al.. (2000). Cytotoxic Activity of 2′,2′-Difluorodeoxycytidine (Gemcitabine) in Poorly Differentiated Thyroid Carcinoma Cells. Thyroid. 10(10). 865–869. 10 indexed citations

19.

White, Jeffrey D., et al.. (1989). Splenosis mimicking an intra-abdominal malignancy. The American Journal of Medicine. 87. 687–690.

20.

White, Jeffrey D., et al.. (1989). Splenosis mimicking an intra-abdominal malignancy. The American Journal of Medicine. 87(6). 687–690. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact